Sales Performance - Total sales for the first quarter of 2025 reached $21,893 million, a 2.4% increase compared to $21,383 million in 2024[3] - U.S. sales increased by 5.9% to $12,305 million, while international sales decreased by 1.8% to $9,588 million[1] - Innovative Medicine segment reported a 2.3% increase in sales, while MedTech segment sales grew by 2.5%[2] - Oncology sales in the U.S. surged by 26.4% to $3,013 million, with international sales increasing by 9.6%[10] - The MedTech segment's total revenue for Q1 2025 was $2,103 million, reflecting a 16.4% increase compared to $1,806 million in Q1 2024[15] - Total MedTech segment sales reached $8,020 million in Q1 2025, a 2.5% increase compared to $7,821 million in Q1 2024[16] - U.S. MedTech sales grew by 5.1% to $4,213 million, while international sales slightly decreased by 0.2% to $3,807 million[16] - The Vision segment in the U.S. reported a 3.4% increase in sales, totaling $566 million, while international sales remained relatively flat with a 0.4% increase[16] Profitability - Gross profit decreased by 2.3% to $14,536 million, with a gross margin of 66.4% compared to 69.6% in the previous year[3] - Net earnings for the first quarter of 2025 were $10,999 million, a significant increase of 237.9% from $3,255 million in 2024[3] - Adjusted net earnings per share (diluted) rose to $2.77, a 2.2% increase from $2.71 in the previous year[5] Expenses and Taxation - The effective tax rate increased to 19.3% from 12.4% year-over-year[3] - Research and development expenses decreased by 8.9% to $3,225 million, representing 14.7% of sales[3] - The company initiated a restructuring program in the MedTech segment, incurring $55 million in expenses during the first quarter of 2025[6] Segment Performance - US sales in the Immunology segment decreased by 10.5% to $2,196 million, while international sales fell by 15.8% to $1,510 million[12] - The Neuroscience segment reported a 8.6% decline in worldwide sales, totaling $1,647 million, with US sales down 8.1% to $968 million[13] - Cardiovascular/Metabolism/Other segment in the US saw a significant increase of 35.4%, reaching $855 million, while international sales decreased by 19.7%[14] - XARELTO sales in the US increased by 33.3% to $690 million, contributing to a total of $690 million worldwide[14] - US sales for STELARA decreased by 29.8% to $981 million, with international sales down 38.9% to $644 million[12] - The Pulmonary Hypertension segment reported a worldwide revenue of $1,025 million, a decrease of 2.3% from $1,049 million in Q1 2024[13] - SPRAVATO sales in the US increased by 45.0% to $276 million, with worldwide sales reaching $320 million, up 41.9%[12] - The company reported a 2.9% decline in US sales for Infectious Diseases, totaling $315 million, while international sales decreased by 1.9% to $487 million[13] Future Projections - Innovative Medicine segment sales for the full year 2024 are projected to reach $2,225 million, with significant contributions from Pulmonary Hypertension products[18] - Rybrevant and Lazcluze generated $93 million in total sales in Q1 2024, with U.S. sales accounting for $36 million[18] - Talvey's sales in the U.S. for Q1 2024 were $50 million, with full-year expectations of $241 million[18] - Other Oncology products generated $328 million in total sales in Q1 2024, with U.S. sales at $93 million[18] - The company anticipates continued growth in the Pulmonary Hypertension segment, with Q1 2024 U.S. sales of $356 million[18] - International sales of Infectious Diseases products reached $1,395 million in Q1 2024, with U.S. sales at $19 million[18] - The overall operational growth for the MedTech segment was 4.1%, excluding currency effects[16]

强生公司将季度股息从每股1.24美元提高至1.30美元。 ...

Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period. Johnson & Johnson projects to report quarterly revenue at $21.57 billion, compared to $21.38 billion a year earlier, according to data from Benzinga Pro. Protagonist Therapeutics, on April 10, announced new data for a pill that trea ...

Core Viewpoint - The analysis emphasizes the potential of Johnson & Johnson (JNJ) stock as a "Buy" due to its competitive advantages and defensibility in the market [1]. Group 1: Company Analysis - Johnson & Johnson is identified as a high-quality company capable of outperforming the market over the long term [1]. - The analysis focuses on companies with a competitive advantage, referred to as an economic moat, which enhances their market position [1]. - The investment strategy is not limited by market capitalization, allowing for a broader range of investment opportunities from large cap to small cap companies [1]. Group 2: Analyst Background - The analyst has a Master's Degree in Sociology with a focus on organizational and economic sociology, and a Bachelor's Degree in Sociology and History [1].

Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its first-quarter 2025 results on April 15. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $21.66 billion and $2.57 per share, respectively. The Zacks Consensus Estimate for J&J’s earnings has declined from $10.58 per share to $10.57 per share for 2025, while that for 2026 has declined from $11.07 per share to $11.02 per share over the past 60 days.Find the latest EPS estimate ...

Core Insights - Analysts expect Johnson & Johnson (JNJ) to report quarterly earnings of $2.57 per share, reflecting a year-over-year decline of 5.2% [1] - Revenue projections stand at $21.66 billion, indicating a 1.3% increase from the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.3% over the past 30 days, showing a reassessment by analysts [1] Revenue and Sales Estimates - The consensus estimate for 'Sales- MedTech- Total' is $8.16 billion, suggesting a year-over-year increase of 4.3% [3] - 'Sales- Innovative Medicine- WW' is projected to reach $13.49 billion, indicating a decline of 0.5% year over year [4] - 'Sales- MedTech- Surgery- WW' is expected to be $2.41 billion, also reflecting a decrease of 0.5% year over year [4] - 'Sales- Innovative Medicine- Oncology- WW' is forecasted to reach $5.58 billion, showing a significant increase of 15.9% from the previous year [4] Specific Product Sales Projections - 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' is estimated at $341.85 million, representing a substantial increase of 117.7% year over year [5] - 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' is projected to be $319.68 million, indicating a year-over-year increase of 42.1% [5] - 'Sales- MedTech- Cardiovascular- ABIOMED- WW' is expected to reach $408.39 million, reflecting a 10.1% increase year over year [6] - 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' is estimated at $94.89 million, suggesting a 3.1% increase from the previous year [6] Orthopaedics Sales Estimates - 'Sales- MedTech- Orthopaedics- Hips- US' is projected at $268.43 million, indicating a decline of 0.6% year over year [7] - 'Sales- MedTech- Orthopaedics- Hips- International' is expected to be $154.50 million, reflecting a 1.6% increase year over year [7] - 'Sales- MedTech- Orthopaedics- Knees- US' is estimated at $240.27 million, suggesting a decrease of 0.7% year over year [8] Overall Performance and Market Position - Organic Sales Growth (Operational growth) is anticipated to reach 3.7%, slightly down from 3.9% reported in the same quarter last year [8] - JNJ shares have returned -7.3% over the past month, compared to a -5.3% change in the Zacks S&P 500 composite [8] - With a Zacks Rank 3 (Hold), JNJ is expected to perform in line with the overall market in the near future [8]

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16SPRING HOUSE, Pa., April 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LE ...

Core Viewpoint - Current stock market sell-offs present challenges but also opportunities for investors to acquire high-quality dividend stocks at lower prices, enhancing passive income generation [1] Group 1: Johnson & Johnson - Johnson & Johnson's stock has declined over 14%, increasing its dividend yield to 3.8%, significantly above the S&P 500's yield of 1.5% [3] - The company holds a AAA bond rating and has a market capitalization exceeding $350 billion, with only $12 billion in net debt against $37 billion in total debt, supported by $25 billion in cash and marketable securities [4] - Johnson & Johnson generated approximately $20 billion in free cash flow last year, covering its dividend outlay of $11.8 billion, and has invested $17.2 billion in R&D and $32 billion in growth opportunities [5] Group 2: Starbucks - Starbucks' stock has dropped over 30%, raising its dividend yield to 3.1%, above its historical average of around 2% [6] - The company faces challenges such as potential tariff impacts on coffee costs and slowed growth, prompting a new CEO to lead a turnaround [7] - Despite these challenges, Starbucks generated over $6 billion in cash last fiscal year, with $2.7 billion in capital spending and $2.6 billion in dividends, maintaining a strong balance sheet with nearly $4 billion in cash and equivalents [8] Group 3: Mid-America Apartment Communities - Mid-America Apartment Communities' stock has fallen nearly 14%, resulting in a dividend yield of 4.1%, with a consistent record of dividend payments since 1994 [9] - The company anticipates improved market conditions as new apartment supply peaks, which should accelerate rent growth later this year and into 2026 [10] - Mid-America has initiated new development projects despite industry headwinds, positioning itself for future growth [10] Group 4: Investment Opportunities - Johnson & Johnson, Starbucks, and Mid-America Apartment Communities are highlighted as high-quality dividend stocks, making the recent stock price declines an attractive opportunity for investors seeking to enhance passive income [11]

While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.The Johnson & Johnson Analyst: Analyst Asad Haider upgraded the rating from Neutral to Buy, while raising the price target from $157 to $172.The Johnson & Johnson Thesis: While the Innovative Medicine business contributes around 65% of the company's revenues, it accounts for 83% of profits, which is why it is " ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]